85% of colon cancer patients don’t respond to anti-PD-L1 due to the lack of immune infiltration while the efficacy of photodynamic therapy (PDT) was limited to hypoxic environment. Thus, a PD-L1 small molecule inhibitor C2 was chose to self-assemble into nanoparticles with photosensitizer, leveraging the unique advantages of the small molecule, the passive targeting nature of nanoparticles, and immunogenic cell death induced by PDT. C2 can form stable nanoparticles C2-Ce6 NPS with remarkable affinity to PD-L1, which was meticulously selected from our compound library through Docking, Homogeneous Time Resolved Fluorescence (HTRF), Surface Plasmon Resonance (SPR), and Molecular dynamics (MD). It demonstrated good safety while achieving a TGI of 90% in the MC38 mouse model with significantly increase of T cell infiltration and reduction of the expression of Ki67, inducing an immunogenic cell death (ICD) proved via the exposure of calreticulin (CRT), which indicated combined treatment is more advantageous. Tumor cells were subjected to both internal and external pressures, which is expected to mitigate the primary resistance and strong immunogenicity of antibody-based immune checkpoint inhibitors, further activate the immune system to broad the scope of immunotherapy indications and simultaneously enhance the efficacy comparing to single PDT.